Proven Effective in Adolescents Ages 13-17
In adolescents ages 13-17, Daytrana® effectively reduced ADHD symptoms as compared with placebo.
ADHD-RS-IV mean total scores—Least squares mean change from baseline to endpoint (ITT population)*
Study 409: Randomized, double-blind, placebo-controlled, outpatient study of 217 subjects (aged 13 to 17) who met DSM-IV-TR® criteria for a primary diagnosis of ADHD. The primary efficacy measure was the mean change in ADHD Rating Scale-IV (ADHD-RS-IV) total score at 7 weeks.
*Endpoint is last nonmissing assessment obtained post-baseline.
Error bars indicate standard error of the mean.
†P<.001 for difference between Daytrana and Placebo treatment.
ADHD-RS-IV=ADHD-Rating Scale-IV; ITT=intent to treat; LS=least squares.
Adapted from Findling RL, Turnbow J, Burnside J, Melmed R, Civil R, Li Y. CNS Spectr. (15)7:2010.
- The Daytrana treatment group demonstrated significant improvement in ADHD-RS-IV total score from baseline to endpoint compared with placebo (P<.001)
- The most commonly reported adverse reactions associated with the Daytrana patch in this study were decreased appetite, headache, irritability, upper respiratory tract infection, nausea, insomnia, dizziness, and decreased weight. Additionally, the majority of the adolescents in this study had minimal to definite skin erythema at the patch application site. Eight Daytrana patients discontinued due to adverse events
Video: Applying and Removing the Patch